|Year : 2017 | Volume
| Issue : 3 | Page : 96-100
Autophagy regulated by miRNAs in colorectal cancer progression and resistance
Andrew Fesler1, Hua Liu1, Ning Wu2, Fei Liu3, Peixue Ling3, Jingfang Ju4
1 Department of Pathology, Stony Brook University, Stony Brook, NY, USA
2 Department of Pathology, Stony Brook University, Stony Brook, NY, USA; Department of Experimental Marine Biology, Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, Shandong, China
3 Shandong Academy of Pharmaceutical Sciences, Jinan, Shandong, China
4 Department of Pathology, Stony Brook University, Stony Brook, NY, USA; Shandong Academy of Pharmaceutical Sciences, Jinan, Shandong, China
|Date of Submission||20-Nov-2016|
|Date of Acceptance||12-Jan-2017|
|Date of Web Publication||8-Jun-2017|
Department of Pathology, Stony Brook University, Room 185, BST L9, Stony Brook, NY 11794, USA
Source of Support: None, Conflict of Interest: None
The catabolic process of autophagy is an essential cellular function that allows for the breakdown and recycling of cellular macromolecules. In recent years, the impact of epigenetic regulation of autophagy by noncoding miRNAs has been recognized in human cancer. In colorectal cancer, autophagy plays critical roles in cancer progression as well as resistance to chemotherapy, and recent evidence demonstrates that miRNAs are directly involved in mediating these functions. In this review, we focus on the recent advancements in the field of miRNA regulation of autophagy in colorectal cancer.
Keywords: Autophagy, cancer stem cell, chemotherapy, colorectal cancer, miRNA
|How to cite this article:|
Fesler A, Liu H, Wu N, Liu F, Ling P, Ju J. Autophagy regulated by miRNAs in colorectal cancer progression and resistance. Cancer Transl Med 2017;3:96-100
|How to cite this URL:|
Fesler A, Liu H, Wu N, Liu F, Ling P, Ju J. Autophagy regulated by miRNAs in colorectal cancer progression and resistance. Cancer Transl Med [serial online] 2017 [cited 2019 Aug 18];3:96-100. Available from: http://www.cancertm.com/text.asp?2017/3/3/96/202229
| Introduction|| |
Twenty-three years after its initial discovery in 1993, the significance of autophagy is being recognized with 2016's Nobel Prize in Physiology and Medicine. In the time since its discovery, extensive research efforts have been made to expand the fundamental understanding of autophagy in basic biology and human diseases including cancer. Autophagy is a conserved, essential, and tightly regulated biological process, in which cells undergo self-destruction. The process of autophagy involves the formation of double-membrane autophagic vacuoles (autophagosomes) around cytoplasmic components. Many of the important genes and pathways that are involved in the process and regulation of autophagy have been identified. These include the autophagy-related genes (ATGs) family of over thirty genes, including ATG1, ATG4, LC3/ATG8, and beclin-1.,, In mammalian cells, starvation conditions as well as other signals lead to inhibition of mTOR, which results in the activation of autophagy initiation kinases ULK1 and ULK2, which phosphorylate ATG13 and FIP200. The ULK1 complex is recruited to the phagophore assemble site and is essential for the initiation of autophagy. The PtdIns3K complex, which includes beclin-1, VPS34, ATG14, PIK3R4, URAG, and AMBRA, is also essential for vesicle nucleation., Formation of the ATG16, ATG5, and ATG12 conjugation complex promotes the elongation of the phagophore. The LC3 conjugation system which involves ATG4, a cysteine protease, also promotes phagophore elongation. Once formed, the mature autophagosome fuses with the lysosome to allow for the degradation of the contents of the autophagosome.,,, The autophagy regulatory circuits and key proteins involved in such process as well as the miRNAs that are involved in the regulation of some of these genes related to colorectal cancer are illustrated in [Figure 1].
|Figure 1: Schematic illustration of autophagy under stress. The autophagy process is divided into phagophore formation, elongation, autophagosome formation, fusion with lysosome, and degradation. Following the initiation stress signaling through the mTOR kinase, the hypophosphorylated ATG13 is maintained, and the autophagic vesicles are formed from the phagophore/isolation membrane to the autophagosome and autolysosome. ATG-11,-13,-17 and ULK complex mediate the early process followed by Beclin-1-hVPS-34-protein complex. hVPS-34/Beclin-1 complex converts PI into PI3P followed by ATG5-ATG12 conjugation and interaction with ATG16 L. Following the LC3 processing events, the nascent complex further undergoes elongation and expansion to form a double-membrane autophagosome. The autolysosome is formed through the docking and fusion of lysosomes docking and fusion with autophagosomes where cargo is degraded to generate amino and fatty acids. miRNAs that involved in colorectal cancer progression and resistance by mediating the initiation and elongation of the autophagy processes are illustrated in the pathway map|
Click here to view
Mounting evidence has revealed that autophagy has important effects on tumor progression. Autophagy has a role in various stages of tumor progression including primary tumor initiation and expansion, invasion, tumor dormancy, metastasis, and resistance to therapy. Autophagy provides critical building blocks for tumor cells to survive during hypoxia and nutrient deprivation. It helps cancer cells gain metabolic fitness during intravasation and invasion.,, It also prolongs the survival of quiescent tumor cells during tumor dormancy. In addition, autophagy aids tumor cells in adapting to a new tissue microenvironment during metastasis to distant organs., Autophagy also promotes tumor stem cell survival in response to acute stress and environmental changes due to chemotherapy and radiation treatment. As a result, autophagy maybe a double-edge sword in cancer treatment. Autophagy triggered by chemotherapy and radiation can effectively eliminate bulk tumors and stromal tissue. At the same time, it also provides a survival advantage for the cancer stem cells during anticancer therapeutic treatment.
Recently, it has been recognized that noncoding miRNAs play key roles in autophagy., miRNAs are noncoding RNA molecules, 18–25 nucleotides in length, that regulate the expression of their target genes by mRNA degradation or translational inhibition. This regulation occurs mainly through interaction at the 3′-UTRs of the target mRNAs.,, Dysregulation of miRNAs has been associated with cancer development and progression, and miRNAs have emerged as a new research frontier for understanding cancer development at the posttranscriptional and translational levels. miRNAs have been found to regulate many cellular processes including apoptosis,,,, differentiation,,, cell proliferation,,,, and autophagy., Some miRNAs important in colorectal cancer and their targets in the autophagy pathway are shown in [Figure 1]. In this review, we highlight some of the recent research efforts on the mechanism and impact of autophagy mediated by miRNAs in colorectal cancer.
| miRNAs Regulation of Autophagy and Colorectal Cancer Progression|| |
Several miRNAs have been found to have important roles in the regulation of autophagy in colorectal cancer, and this regulation can influence cancer progression. Recent studies from our group show that miR-140 directly targets Smad2, and through repression of Smad2, overexpression of miR-140 in colon cancer cell lines inhibits invasion, proliferation, and induces cell cycle arrest. Ectopic expression of miR-140 in colorectal cancer stem cells leads to the disruption of autophagy, inhibiting tumor stem cell growth and sphere formation. We have identified ATG12 as one of the main targets of miR-140 involved in autophagy. ATG12 is important in autophagosome elongation [Figure 1] and [Table 1]. Furthermore, overexpression of miR-140 in colon cancer stem cells abolished tumor formation and metastasis in vivo. In addition, there is a progressive loss of miR-140 expression from normal colorectal mucosa to primary tumor tissues, with further reduction in liver metastatic tissues. Higher miR-140 expression is significantly correlated with better survival in patients with stage III and IV colorectal cancer. This suggests that miR-140 is a key regulator in colorectal cancer progression and metastasis, and miR-140 disrupts colon cancer stem cell growth through interrupting autophagy.
|Table 1: miRNAs and their important autophagy.related targets in colorectal cancer|
Click here to view
We also discovered that miR-502 directly suppresses autophagy by targeting the small GTPase, RAB1B, in colon cancer cell lines. RAB1B modulates autophagic activity through the regulation of autophagosome formation [Figure 1]. RAB1B regulates vesicle trafficking and directly impacts autophagy., Ectopic expression of miR-502 in HCT-116 cells interrupted autophagic flux under acute and prolonged nutrient starvation and significantly decreased colon cancer cell growth. Inhibition of both p53 and RAB1B, the mediators for autophagy, can reproduce this phenotype, suggesting that autophagy plays an important role in its tumor suppressive function. Profiling of human colon cancer samples reveals that miR-502 is downregulated in tumor tissue compared to normal tissue. Ectopic expression of miR-502 in human colon cancer xenografts can significantly reduce tumor size, indicating miR-502 has potential as an adjuvant treatment for patients with colon cancer.
miR-106a and miR-106b have been shown to inhibit starvation-induced autophagy in colon cancer cells. This autophagy inhibition is the result of targeting of multiple important genes including ATG16 L and ATG12. Starvation-induced autophagy is also inhibited by miR-183 targeting UVRAG, which normally promotes autophagosome formation in colon cancer.
As opposed to these miRNAs that inhibit autophagy, miR-124 acts as tumor suppressor gene by inducing apoptosis and autophagy in colon cancer both in vitro and in vivo tumor xenografts. miR-124 targets polypyrimidine tract-binding protein 1 (PTB1), which is a splicer of pyruvate kinase muscles 1 and 2 (PKM1 and PKM2), and induces the switching of PKM isoform expression from PKM2 to PKM1. PKM2 is an activator of mTOR, so by switching expression to PKM1, mTOR activity is repressed [Figure 1]. These findings suggest that miR-124 acts as a tumor suppressor and a modulator of energy metabolism through a PTB1/PKM1/PKM2 feedback cascade in human colorectal tumor cells. miR-18a has been reported as a potential tumor suppressor by inducing apoptosis in colon cancer cells through the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). The function of miR-18a provides another mode of miRNA action on the degradation of key targets such as hnRNP A1 through autophagy in cancer. miR-18a also induces autophagy through inhibition of ATM which activates AMPK, an inhibitor of mTOR. These miRNAs all have shown an ability to regulate autophagy in colon cancer. This regulation influences colon cancer growth and progression.
| miRNA, Autophagy, and Resistance Mechanisms|| |
In addition to these miRNAs that regulate autophagy and influence cancer growth and progression, other miRNAs have been found to influence resistance in colon cancer through their regulation of autophagy. It has been found that under hypoxia, hypoxia-inducible factor (HIF)-1α induces miRNA-210 which, in turn, enhances autophagy and reduces radiosensitivity by downregulating Bcl-2 expression in colon cancer cells. This work provides experimental evidence that the expression of miR-210 in human colon cancer cell lines, SW480 and SW620, is significantly increased after hypoxia and forms a positive feedback loop with HIF-1α. As Bcl-2 is mediating both apoptosis and autophagy, downregulation of Bcl-2 by miR-210 reduces radiosensitivity in colon cancer cell lines. This study provides experimental evidence that autophagy may contribute to the reduction of radiosensitivity in hypoxic environments, and the process is mediated through the HIF-1α/miR-210/Bcl-2 pathway in human colon cancer cells.
miR-409-3p is a miRNA that inhibits autophagy. miR-409-3p inhibits autophagy by targeting Beclin-1. This autophagy regulation results in enhanced sensitivity to oxaliplatin. miR-22 has also been shown to influence colon cancer cell resistance to chemotherapy. In colon cancer cells, miR-22 can inhibit autophagy and promote apoptosis. This is the result of targeting BTG1. Overexpression of miR-22 in colon cancer cells, increased sensitivity to 5-FU, is one of the main chemotherapeutic agents used in the treatment of colorectal cancer. As chemoresistance is a major challenge faced in the treatment of colorectal cancer, these miRNAs and their regulation of autophagy have intriguing potential to improve patient outcomes. A summary of miRNAs and their autophagy-related targets in colorectal cancer is shown in [Table 1].
| Conclusion and Future Perspectives|| |
In summary, it is clear that a number of miRNAs regulate autophagy under various acute genotoxic stress situations in colorectal cancer. Autophagy, regulated by miRNAs, provides tumor cells with an acute response mechanism to genotoxic stress conditions such as chemotherapy. Tumor cells also grow under stress conditions due to hypoxia and/or nutrient deprivation; as a result, miRNAs that can modulate autophagy will impact cancer cell survival. This may be of particular importance in chemoresistant cancer stem cells. As tumor cells are highly heterogeneous, it might be an ideal two-hit strategy to eliminate bulk tumor cells by first using tumor suppressive miRNAs that can effectively eliminate tumor cells through autophagy. The second step will be to use the miRNAs that can disrupt autophagy to prevent cancer stem cell survival by eliminating the building blocks provided by autophagy. Therefore, it is quite conceivable that modulating miRNA will provide a new direction to change cancer cells in response to stress by altering the autophagy process, and in turn will provide new therapeutic strategies to overcome chemoresistance.
Financial support and sponsorship
This study was supported by the funding from the National Institute of Health R01CA155019 (J. Ju), R01CA197098 (J. Ju).
Conflicts of interest
There are no conflicts of interest.
| References|| |
Tsukada M, Ohsumi Y. Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. FEBS Lett
1993; 333 (1–2): 169–74.
Ohsumi Y. Historical landmarks of autophagy research. Cell Res
2014; 24 (1): 9–23.
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, et al
. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd
2016; 12 (1): 1–222.
Zhou S, Zhao L, Kuang M, Zhang B, Liang Z, Yi T, Wei Y, Zhao X. Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde? Cancer Lett
2012; 323 (2): 115–27.
Fu LL, Wen X, Bao JK, Liu B. MicroRNA-modulated autophagic signaling networks in cancer. Int J Biochem Cell Biol
2012; 44 (5): 733–6.
Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol
2010; 22 (2): 132–9.
Fullgrabe J, Klionsky DJ, Joseph B. The return of the nucleus: transcriptional and epigenetic control of autophagy. Nat Rev Mol Cell Biol
2014; 15 (1): 65–74.
Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ
2011; 18 (4): 571–80.
Yu ZQ, Ni T, Hong B, Wang HY, Jiang FJ, Zou S, Chen Y, Zheng XL, Klionsky DJ, Liang Y, Xie Z. Dual roles of Atg8-PE deconjugation by Atg4 in autophagy. Autophagy
2012; 8 (6): 883–92.
Parzych KR, Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal
2014; 20 (3): 460–73.
Lippai M, Szatmári Z. Autophagy-from molecular mechanisms to clinical relevance. Cell Biol Toxicol
Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, Kim H, Neufeld TP, Dillin A, Guan KL. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol2013; 15 (7): 741–50.
He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet
2009; 43: 67–93.
Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer
2007; 7 (12): 961–7.
Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y.In vivo
analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell
2004; 15 (3): 1101–11.
Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, White E. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev
2007; 21 (13): 1621–35.
Jin S, White E. Role of autophagy in cancer: management of metabolic stress. Autophagy
2007; 3 (1): 28–31.
Brech A, Ahlquist T, Lothe RA, Stenmark H. Autophagy in tumour suppression and promotion. Mol Oncol
2009; 3 (4): 366–75.
Mowers EE, Sharifi MN, Macleod KF. Autophagy in cancer metastasis. Oncogene
2016. doi: 10.1038/onc. 2016.333.
Sharifi MN, Mowers EE, Drake LE, Collier C, Chen H, Zamora M, Mui S, Macleod KF. Autophagy promotes focal adhesion disassembly and cell motility of metastatic tumor cells through the direct interaction of paxillin with LC3. Cell Rep
2016; 15 (8): 1660–72.
Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell
2006; 10 (1): 51–64.
Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov
2007; 6 (4): 304–12.
Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Casey T, Tsirigos A, Migneco G, Witkiewicz A, Balliet R, Mercier I, Wang C, Flomenberg N, Howell A, Lin Z, Caro J, Pestell RG, Sotgia F, Lisanti MP. The autophagic tumor stroma model of cancer or “battery-operated tumor growth”: a simple solution to the autophagy paradox. Cell Cycle
2010; 9 (21): 4297–306.
Zhai H, Fesler A, Ju J. MicroRNA: a third dimension in autophagy. Cell Cycle
2013; 12 (2): 246–50.
Frankel LB, Lund AH. MicroRNA regulation of autophagy. Carcinogenesis
2012; 33 (11): 2018–25.
Lee RC, Feinbaum RL, Ambros V. The C. elegans
heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell
1993; 75 (5): 843–54.
Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans
1993; 75 (5): 855–62.
He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet
2004; 5 (7): 522–31.
Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer
2010; 10 (6): 389–402.
Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell
2003; 113 (1): 25–36.
Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res
2005; 65 (14): 6029–33.
Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer
2006; 94 (6): 776–80.
Ghodgaonkar MM, Shah RG, Kandan-Kulangara F, Affar EB, Qi HH, Wiemer E, Shah GM. Abrogation of DNA vector-based RNAi during apoptosis in mammalian cells due to caspase-mediated cleavage and inactivation of Dicer-1. Cell Death Differ
2009; 16 (6): 858–68.
Tang F. Small RNAs in mammalian germline: tiny for immortal. Differentiation
2010; 79 (3): 141–6.
Navarro F, Lieberman J. Small RNAs guide hematopoietic cell differentiation and function. J Immunol
2010; 184 (11): 5939–47.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature
2005; 435 (7043): 828–33.
Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res
2007; 67 (16): 7713–22.
Zhai H, Fesler A, Ba Y, Wu S, Ju J. Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy. Oncotarget
2015; 6 (23): 19735–46.
Zhai H, Song B, Xu X, Zhu W, Ju J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene
2013; 32 (12): 1570–9.
Zoppino FC, Militello RD, Slavin I, Alvarez C, Colombo MI. Autophagosome formation depends on the small GTPase Rab1 and functional ER exit sites. Traffic
2010; 11 (9): 1246–61.
Plutner H, Cox AD, Pind S, Khosravi-Far R, Bourne JR, Schwaninger R, Der CJ, Balch WE. Rab1b regulates vesicular transport between the endoplasmic reticulum and successive Golgi compartments. J Cell Biol
1991; 115 (1): 31–43.
Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol
2009; 10 (8): 513–25.
Zhai Z, Wu F, Chuang AY, Kwon JH. miR-106b fine tunes ATG16L1 expression and autophagic activity in intestinal epithelial HCT116 cells. Inflamm Bowel Dis
2013; 19 (11): 2295–301.
Huangfu L, Liang H, Wang G, Su X, Li L, Du Z, Hu M, Dong Y, Bai X, Liu T, Yang B, Shan H. miR-183 regulates autophagy and apoptosis in colorectal cancer through targeting of UVRAG. Oncotarget
2016; 7 (4): 4735–45.
Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama K, Akao Y. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett
2015; 363 (1): 17–27.
Fujiya M, Konishi H, Mohamed Kamel MK, Ueno N, Inaba Y, Moriichi K, Tanabe H, Ikuta K, Ohtake T, Kohgo Y. microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1. Oncogene
2014; 33 (40): 4847–56.
Qased AB, Yi H, Liang N, Ma S, Qiao S, Liu X. MicroRNA-18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells. Mol Med Rep
2013; 7 (2): 559–64.
Sun Y, Xing X, Liu Q, Wang Z, Xin Y, Zhang P, Hu C, Liu Y. Hypoxia-induced autophagy reduces radiosensitivity by the HIF-1α/miR-210/Bcl-2 pathway in colon cancer cells. Int J Oncol
2015; 46 (2): 750–6.
Tan S, Shi H, Ba M, Lin S, Tang H, Zeng X, Zhang X. miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy. Int J Mol Med
2016; 37 (4): 1030–8.
Zhang H, Tang J, Li C, Kong J, Wang J, Wu Y, Xu E, Lai M. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett
2015; 356 (2 Pt B): 781–90.
|This article has been cited by|
||Autophagy in exposure to environmental chemicals
| ||Maija Pesonen,Kirsi Vähäkangas |
| ||Toxicology Letters. 2019; |
|[Pubmed] | [DOI]|
||The Role of Extracellular Vesicles as Modulators of the Tumor Microenvironment, Metastasis and Drug Resistance in Colorectal Cancer
| ||Kodappully S. Siveen,Afsheen Raza,Eiman I. Ahmed,Abdul Q. Khan,Kirti S. Prabhu,Shilpa Kuttikrishnan,Jericha M. Mateo,Hatem Zayed,Kakil Rasul,Fouad Azizi,Said Dermime,Martin Steinhoff,Shahab Uddin |
| ||Cancers. 2019; 11(6): 746 |
|[Pubmed] | [DOI]|
||Role of DDX53 in taxol-resistance of cervix cancer cells in vitro
| ||Su Yeon Park,Won jin Kim,Jae hwan Byun,Jae Jun Lee,Dooil Jeoung,Sung Taek Park,Youngmi Kim |
| ||Biochemical and Biophysical Research Communications. 2018; |
|[Pubmed] | [DOI]|
||Decreased Expression of MicroRNA-107 in B Lymphocytes of Patients with Antibody-Mediated Renal Allograft Rejection
| ||Zhe-Wei Zhang,Ming Wang,Jun-Jie Hu,Gang Xu,Yong Zhang,Nan Zhang |
| ||The Tohoku Journal of Experimental Medicine. 2018; 246(2): 87 |
|[Pubmed] | [DOI]|
||Barbaloin loaded polydopamine-polylactide-TPGS (PLA-TPGS) nanoparticles against gastric cancer as a targeted drug delivery system: Studies in vitro and in vivo
| ||Yi-Ran Wang,Shi-Yan Yang,Guang-Xia Chen,Ping Wei |
| ||Biochemical and Biophysical Research Communications. 2018; 499(1): 8 |
|[Pubmed] | [DOI]|
||Autophagy in health and disease: A comprehensive review
| ||Sarbari Saha,Debasna P. Panigrahi,Shankargouda Patil,Sujit K. Bhutia |
| ||Biomedicine & Pharmacotherapy. 2018; 104: 485 |
|[Pubmed] | [DOI]|